Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 15, 2008 (Vol. 28, No. 20)


  • Clever idea
  • Not appropriate for all searches
“Give me a ‘G’, give me an ‘O’, give me a ‘PubMed’ too. Roll it all together. Make something new. GoPubMed, GoPubMed, GoPubMeddddddddd.” OK, the spirit moved me, which may be what also happened when the designers of this site came up with the idea for it. Simply put, GoPubMed takes input, makes PubMed inquiries, and then sorts the results. It may sound trivial, but it’s not. I used my name “Ahern” as a search term and quickly retrieved over 900 hits. Making sense of those hits was made easier by the fact that a panel on the left side organized the results according to topic, author name, journal published, and time of publication. If I wanted to bring up all of the hits for M. Ahern, it was a simple click. Similarly, getting a list of all articles in 2003 was another click. This is one of the best ways I’ve seen to wade through the sometimes massive results of a PubMed search.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »